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Interleukin 20 regulates dendritic cell
migration and expression of co-stimulatory
molecules
Rikke Bech1,2†, Babak Jalilian2†, Ralf Agger3, Lars Iversen1, Mogens Erlandsen4, Kristian Otkjaer1, Claus Johansen1,
Søren R. Paludan2, Carina A. Rosenberg2, Knud Kragballe1 and Thomas Vorup-Jensen2,5,6*
Abstract
Background: Psoriasis is an inflammatory disease characterized by leukocyte skin infiltration. Interestingly, recent
works suggest that the migration of dendritic cells (DCs) is abnormal in psoriatic skin. DCs have significant role in
regulating the function of T lymphocytes, at least in part influenced by the local environment of cytokines. In
psoriatic skin lesions the expression of IL-20 is highly up-regulated. It is unclear if this cytokine has any influence on
DCs.
Methods: Here, we investigated the influence of IL-20 in monocyte-derived dendritic cell (MDDCs) in vitro. This
work addressed IL-20 effects on DC maturation, receptor expression and signaling. By use of extra cellular matrix
components mimicking the skin environment, we also studied the functional effects of IL-20 on the chemotactic
migration of DCs. Based on the recent finding that CD18 integrin are shed during migration of myeloid leukocytes,
the concentration of these adhesion molecules was measured in MDDCs culture supernatants post migration.
Results: Following stimulation with IL-20, immature human MDDCs enhanced the expression of the co-stimulatory
molecule CD86, further enabling activation of the p38 MAPK, but not the STAT3, pathway. IL-20 increased the
migration of MDDCs in a biphasic response narrowly controlled by the interleukin concentration. A concomitant
change in the shedding of CD18 integrins suggested that these adhesion molecules play a role in the migration of
the MDDCs through the extracellular matrix layer.
Conclusion: Taken together, our findings points to a possible, yet subtle, role of IL-20 in DCs migration. The
biphasic response suggests that the aberrant IL-20 expression in psoriasis impedes DC migration, which could be a
part of the processes that precipitates the dysregulated inflammatory response associated with this disease.
Keywords: Dendritic cells, Psoriasis, Interleukin (IL)-20, CD18 integrins, Cell migration
Background
IL-20 belongs to the IL-10 family of λ interleukins with
15–39 % identical primary structure in pairwise compar-
isons [1, 2]. IL-10 interleukins contribute to a great
variety of cellular processes, which regulate the immune
system, including antiviral activity, antibacterial proteins
secretion, cell-growth stimulation, acute phase response,
wound healing, anti-tumor activity, as well as induction
of apoptosis [1, 2]. However, studies connecting the
function of IL-20 to specific leukocyte subsets are still
lacking. Studies showed that IL-20 expression in humans
is associated with chronic inflammation disorders such
as psoriasis and rheumatoid arthritis [3]. Furthermore,
the over expression of IL-20 in transgenic mice gener-
ated psoriasis-like skin lesions [4] and treatment of
human skin xenografts with IL-20 induced psoriasis-like
skin lesions [5].
In psoriasis, epidermal keratinocytes are a major
source of IL-20 synthesis and the transcriptional level of
IL-20 is strongly upregulated in psoriatic skin lesions [5].
Other studies suggest that monocytes and maturing DCs
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are additional sources of IL-20 [2, 6] although more re-
cent work also suggest that papillary mononuclear cells
possibly may take up IL-20 released into the epidermis
by keratinocytes [7]. DCs expressing CD40, CD86, and
HLA-DR are abundant in psoriatic skin, while resolution
of psoriatic lesions results in reduction of DC infiltra-
tion [8]. Normal skin contains an abundant subset of
CD1a + CD207 + immature DCs, also referred to as
Langerhans cells (LC). Appropriate uptake of antigen
prompts the migration of LC from epidermis to the
dermis and draining lymph nodes through the base-
ment membrane. Cumberbatch et al. reported that
the mobilization of immature DCs following IL-1β
and TNFα stimulation was impaired in non-lesional
psoriatic skin compared to the non-inflamed skin
where these cytokines support the DCs migration [9].
Intriguingly, it was recently demonstrated that these
findings were not due to a defect in DCs function
[10] pointing to the cytokine milieu as a factor in the
migrational impairment. However, there has been a
paucity of studies at the cellular level to more pre-
cisely investigate these factors.
Integrins are heterodimeric cell adhesion molecules,
composed of one alpha and one beta chain, which sup-
port cell-cell and cell-extracellular matrix (ECM) adhe-
sion [11]. The family of β2 integrins (CD18) includes
CD11a/CD18 (LFA-1), CD11b/CD18 (Mac-1 or comple-
ment receptor 3), and CD11c/CD18 (p150,95 or comple-
ment receptor 4) with an expression restricted to
leukocytes. The role of CD11a/CD18 in psoriasis is well
established from the clinical application of Efalizumab
[12], which blocks the function of CD11a/CD18 and
hence decreasing the influx of DCs into psoriatic skin
[8]. Recently, it has been shown that the plasma concen-
tration of shed CD18 integrins is lower in arthritis
patient samples compared with healthy controls. By
contrast, the concentration in synovial fluid from the
inflamed arthritis patients is elevated compared with
the less inflamed osteoarthritis patients [13, 14]. This
points to shedding of CD18 in the zone of inflamma-
tion supporting the hypothesis of a link between cel-
lular migration and shedding of CD18 [15]. A few
studies have implicated CD18 shedding as part of
chemotaxis and exposure to stress shear in neutro-
phils [16, 17], but experimental studies comparing mi-
gration and the shedding of CD18 in leukocytes
central to adaptive immunity have not been reported
earlier.
In the present study we established culturing condi-
tions to enable the differentiation of human peripheral
monocytes into DCs with an immature phenotype. We
investigated the influence of IL-20 on the maturation
of these monocyte-derived DCs (MDDC)s, interleukin
receptor expression and signaling, as well as the
function of MDDCs in cell migration and shedding of
adhesion receptors. We report that IL-20 influences
the expression of co-stimulatory molecules. The
MDDCs express both IL-20RA and IL-20RB, which
permits signaling involved in phosphorylation of p38.
We found that IL-20 influenced the migration of
MDDCs. These findings readily suggest a link be-
tween the function of IL-20 and trapping of DCs in
psoriatic skin.
Methods
Isolation of monocytes from human blood
Blood samples were collected from healthy human
donors according to protocols for obtaining samples
from humans approved by the institutional ethical re-
view committee. Monocytes were, then, isolated using
Ficoll Paque PLUS (GE Healthcare, Little Chalfont,
UK) and “Monocyte Negative Isolation Kit”™ (Gibco-
Life, Waltham, MA) according to the instructions by
the manufacturer. The monocytes were resuspended
in RPMI-1640 culture medium containing 20mg/ml
gentamicin, 2 mM l-glutamine, and 2 % (v/v) heat-
inactivated human serum (Gibco-Life).
Differentiation of monocytes into MDDCs
Isolated monocytes were cultured for a total of seven
days in 6-cm Petri dishes. (Nunclon Surface™, 150288;
Nunc, Kamstrup, Denmark). Cultures were kept in sup-
plemented RPMI-1640 culture medium (described
above) and incubated at 37 °C in an atmosphere with 5
% (v/v) CO2 and 80 % relative humidity (Fig. 1). The dif-
ferentiation was initiated on Day 1 (Fig. 1a) by 20 ng/
ml recombinant IL-4 (PeproTech EC, London, UK)
and 100 ng/ml GM-CSF (Leukine Sargramostim™,
Berlex, Richmond, CA). On Day 3 the cultures received
1.05 ml of culture medium containing 67 ng/ml IL-4
and 300 ng/ml GM-CSF and on Day 5 a volume of
4.55 ml culture medium containing 40 ng/ml IL-4
and 200 ng/ml GM-CSF was added. Following add-
itional cultivation for two days (Incubation I, Fig. 1b)
the cells were harvested by flushing the Petri dishes
with ice-chilled culture medium and analyzed by flow cy-
tometry as described below. As a positive control on the
expression of maturation markers, cells were also stimu-
lated (Fig. 1b) with 10 ng/ml of LPS (Sigma-Aldrich, St.
Louis, MO) on Day 6. To investigate the role of IL-20 in
maturation of DCs, cells were incubated for 4-6 h with re-
combinant human IL-20 [18] (Batch 022 KMK, Novo
Nordisk, Måløv, Denmark) at concentrations of 0.0001-
5000 ng/ml (Fig. 1b).
Characterization of MDDCs surface marker expression
Analysis of the MDDCs expression of cell surface
markers was carried out by flow cytometry for which
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antibodies labelled with surface markers using anti-
bodies to HLA-DR (BD Bioscience, Franklin Lakes,
NJ), CD1a (BD Biosciences), CD1c (Miltenyi Biotec
Norden, Lund, Sweden), CD14 (DAKO, Copenhagen,
Denmark), CD40 (BD Biosciences), CD80 (Immunotech,
Marseilles, France), CD83 (BD Biosciences), CD86 (BD
Biosciences). FlowJo™ software was used (ver. 7.2.4; Tree
Star, Inc., Ashland, OR) for data analyses.
Quantification of IL20RA, IL20RB, and IL22RA gene
expression in MDDCs
Cells were lysed by adding 100 μl of cell lysis buffer,
repeated pipetting and storing at -80 °C (Promega
Biotech AB, Nacka, Sweden). Total RNA was purified
with the SV Total RNA Isolation System™ (Promega)
following the manufacturer’s instruction. Quantitative
reverse transcriptase (qRT) PCR was performed on
RNA extracted from the MDDCs of 6 healthy donors
and using Taqman™ Reverse Transcription Reagents with
random hexameric oligonucleotides following the manu-
facturer’s instructions (Applied Biosystems, Waltham,
MA). The samples with complementary DNA (cDNA)
were investigated by PCR using IL20RA, IL20RB, IL22R,
and GAPDH primers (Applied Biosystems). The gene ex-
pression was quantified by the relative standard curve
method [19].
Interleukin-induced STAT, ERK, JNK, and p38 MAPK
phosphorylation
Phosphorylation of signaling molecules in MDDCs
treated with IL-20, IL-10 (cat.no. 200-10; Perprotech
EC, London, UK), IL-19 (1035-IL/CF; R&D systems,
Minneapolis, MN) or IL-24 (1965-IL/CF; R&D systems)
at concentrations of 0.001, 0.01, 0.1, 1, or 10 ng/ml for
10 or 30 min before harvest (Fig. 1b) was analyzed by
commercially available multiplex assays. The 3-plex
assay measured the phosphorylation level of STAT1 (of
residue of Tyr-701), STAT3, and STAT5a⁄b with anti-
body coupled beads (LHO0005; Invitrogen, Waltham,
MA). The 4-plex assay (171-304004; Bio-Rad Laboratories,
Inc., Hercules, CA) determined the phosphorylation level
of p38 MAPK (of residue Thr-180 & Tyr- 182) as well as
ERK1/ERK2, JNK, and STAT6 also by antibody-coupled
beads.
Assays for measuring the influence of interleukins on
MDDCs migration
Migration assays were performed with the basement
membrane extract (BME) Cell Invasion Assay™ (Trevigen,
Gaithersburg, MD). Membranes with a pore size of 8 μm
separating the upper and lower chambers in modified
Boyden chambers were coated with BME according to the




Fig. 1 Schematic overview of the MDDCs cultures. a All cultures were initiated by 5 days of treatment of monocytes with GM-CSF and IL-4.
During culture the medium and cytokines were replenished as indicated. b Separate incubations were applied for analyzing the influence
of IL-20 and other stimulants on maturation (I-III), signaling (IV-V), or function (VI-VII). c The influence of the stimulants was tested with
cellular-based assays
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with LPS or cytokines or without stimulations, (Fig. 1b)
were then added to upper chambers of the modified
Boyden chambers over the layer of coagulated BME.
RPMI-1640/Gln with 10 % (v/v) human AB serum
was added to the lower chamber as chemoattractant.
Following one hour of incubation, migrated cells were
released from the lower side of the membrane and
stained with fluorescent dye was used to enable quan-
tification in the Victor™ X3 multi label plate reader
(PerkinElmer, Waltham, MA).
Light microscopy and assays for CD18 shedding
MDDCs were cultured in Lab-Tek 2™ chamber slides
(NUNC) with a quartz bottom. Imaging was made with a
Leica (Wetzlar, Germany) inverted microscope equipped
with an Automatic Thermocontrol System™ kept at 37 °C.
For each slide a total of 10 images were made and com-
bined by “z stacking” (Leica Application Suite). Detection
of soluble (s)CD18 (Fig. 1b) in a time-resolved immuno-
fluorometric assay (TRIFMA) in MDDC culture superna-
tants was carried out as described earlier [13, 20].
Statistical methods and calculations on experimental data
Expression of cell surface markers were analyzed by flow
cytometry and compared using paired two-tailed Student’s
t-tests with Bonferroni’s corrections of the level of signifi-
cance. Findings were considered significant if p <0.05/N,
where N is the number of comparisons. A similar analysis
was applied for data for the phosphorylation of STAT3
and p38 as well as data on expression of the IL-20
receptors.
The migration of MDDCs through BME layer, in re-
sponse to interleukin treatment, was compared based on
the number of migrated cells (MC) essentially reflecting
the rate of migration since the BME layer thickness and
number of applied cells were kept constant for the com-
pared experiments. The mean value was obtained from











Variance homogeneity (Bartlett’s test) was obtained by
inverse transformation of the number of migrated cells
1=MC
 
. The different levels of IL-20 concentrations
were compared by ANOVA with repeated measurements
of 1/MC. A dose-response relationship between IL-20
concentration and MC was investigated based on a
quadratic polynomial with
1=MC ¼ a log10ρIL−20
 2 þ b log10ρIL−20 þ c;
ð2Þ
where ρIL-20 is the mass concentration of IL-20 (in g/l)
and a, b, and c are the polynomial constants determined
from fitting Eq. 2 to the experimental data. In this model,
the dose-response relationship between the IL-20 concen-
tration and the harmonic mean of MC permit both posi-
tive and negative effects of IL-20 on MC. The data were
tested against the hypothesis of no overall effect of IL-20,
i.e., a = b = 0, reducing Equation 2 to 1=MC ¼ c. For each
MDDCs culture, the shedding of CD18 was analyzed by
TRIFMA in three dilutions of the culture supernatant in
duplicate wells. The influence of IL-20 treatment was
tested by an ANOVA with the degrees of freedom cor-
rected for the repeated measurements made for each
culture.
Results and discussion
Effects of LPS and IL-20 on maturation of MDDCs
Several cytokines are known to play a role in the matur-
ation of DC by enhancing the cell surface expression of
proteins central to the function of DC, notably those in-
volved in Ag presentation, signaling, and co-stimulation.
To permit a study of such effects, we established a pro-
cedure (Fig. 1) for differentiating in vitro human mono-
cytes into DC-like cells with a cell surface marker
expression resembling immature DC in the skin. Follow-
ing 6 days of culture, these cells showed an excellent via-
bility (97–99 %). The maturation state of the MDDC
was investigated by flow cytometry comparing the cell
surface expression of maturation markers with or with-
out LPS stimulation, which is a well-characterized agent
for maturating DC. The panel of markers reflecting the
Ag-presentation capability was chosen to include MHC
class II molecules (HLA-DR shown in Additional file 1:
Figure S1A) and the MHC-like molecules CD1a and
CD1c (Additional file 1: Figure S1B,C). The signaling
molecule CD40 (Additional file 1: Figure S1D), the T-
cell stimulatory and regulating molecule CD83, and the
costimulatory molecules CD80 and CD86 (Additional
file 1: Figure S1E-G) are important in the signaling be-
tween DC and T lymphocytes [21]. CD14 is a pattern
recognition molecules involved in the recognition of
LPS and thus contributes to functions involved in the
early events of immune recognition in case of microbial
challenge [22].
The MDDCs were used to investigate the potential
role of IL-20 in maturation of DCs (Fig. 2). Treatment of
these cells with 500 or 5000 ng/ml of IL-20 for 4–6 h,
significantly increased (p = 0.0017 and 0.0063, respect-
ively) the percentage of CD86-posive cells (Fig. 2a).
Interestingly, in a paired comparison with untreated
cultures, the largest increment in CD86 positive cells
following IL-20 treatment was observed in MDDCs
cultures with relatively few CD86 positive cells before
treatment, i.e. in the most immature MDDCs (data not
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shown). Furthermore, compared to untreated cells
(Fig. 2b), only a subset of MDDCs responded to the
treatment with 500 ng/ml IL-20 (Fig. 2d,e) and reached
a higher CD86 expression level, surpassing the CD86
level following the treatment with LPS (Fig. 2c-e). Un-
like the maturation induced by LPS (Additional file 1:
Figure S1), no changes in the expression level of CD40
or the percentage of MDDCs positive for CD40
(Fig. 2d), HLA-DR, CD80, or CD83 (data not shown)
was detected following stimulation with IL-20.
IL-20 receptor expression, interleukin binding, and
signaling
The MDDC transcription of receptors for IL-20 was an-
alyzed by quantitative RT-PCR (qRT-PCR) with the sig-
nals normalized to transcription from the GAPDH gene.
Unstimulated MDDCs made transcripts of both IL20RA
and IL20RB genes (Fig. 3a-d) suggesting that required
proteins were expressed to ensure a functional IL-20 re-
ceptor complex. The IL20R mRNA transcription was
not affected by treating the MDDCs with LPS nor IL-20
in concentrations of 0.1 or 1 ng/ml and incubation times
varying from 30 min to 6 h (Fig. 3b,d). To explore other
sources of IL-20 receptors the transcription from the
IL22R locus was also analyzed. IL22R mRNA was not
expressed in untreated MDDCs (Fig. 3e,f ). In two of six
donors a treatment with 10 ng/ml LPS for 24 h induced
transcription of IL22R mRNA (Fig. 3f ). The LPS-
induced IL22R mRNA transcription was 0.3 relative to
GAPDH.
To investigate the functional relevance of the IL20R
expression, we analyzed the response to IL-10 family in-
terleukins, which share the property of binding to both
of these receptor complexes. By comparing the outcome
considering phosphorylation of p38 MAPK and STAT3
substrates, we collected more information on the signal-
ing pathway usage by these interleukins (Fig. 4). MDDCs
were incubated with IL-10, a known potent activator of






Fig. 2 CD86 expression of IL-20-treated MDDCs. Cells were treated
according to Incubation III outlined in Fig. 1b with addition of
IL-20 to the culture 4-6 h before harvest. IL-20 was applied in
concentrations (ρIL-20) of 0.001-5000 ng/ml and cells from 3-11
donors were analyzed. Results were based on MDDCs from
Donors #1-25. a The percentage of CD86 positive MDDCs following
incubation without or with IL-20 in the concentration stated on the
abscissa. Bars indicate the statistical significant difference between
treated and non-treated MDDCs cultures as analyzed by a t-test (b-d).
Flow cytometric determination of the level of staining with antibodies
to CD40 and CD86. As a representative case, results from the analysis
of Donor 1 is shown, either as unstimulated (b), stimulated with
LPS (c), or stimulated with IL-20 (d). e Histogram showing the
distribution of staining intensities with Ab to CD86, either for
untreated culture or for cultures treated with IL-20
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influence on phosphorylation of the p38 (Fig. 4a) while
pretreatment with 10 ng/ml IL-10 induced a 4,000-fold
increase in the STAT3 phosphorylation (p = 0.009) com-
pared with untreated MDDCs (Fig. 4b). IL-19 appeared
neither to influence the p38 nor the STAT3 phosphoryl-
ation (Fig. 4c,d). By contrast, both IL-20 (Fig. 4e) and
IL-24 (Fig. 4g) increased the p38 phosphorylation, but
these interleukins did not significantly alter the STAT3
phosphorylation (Fig. 4f,h). The p38 phosphorylation
was altered following the treatment with of 0.1 ng/ml of
both cytokines individually administered (Fig. 4e,g).
Interestingly, the IL-20 induced p38 phosphorylation
peaked at 0.1 ng/ml, while lower or higher concentra-
tions produced lower mean values among the tested cell
cultures (Fig. 4e). In two of three donors, the p38 phos-
phorylation level was more than doubled when MDDCs
were pretreated with 0.1 ng/ml of IL-20. However, the
increase in p38 phosphorylation level was not statis-
tically significant when analyzed with a paired t-test
(p = 0.1299). Following the pre-treatment of MDDCs
with IL-24, the p38 phosphorylation level was raised
in all samples and for all IL-24 concentrations. For
samples pretreated with IL-24 at concentrations of
0.001 and 0.1ng/ml, the increase in the mean phos-
phorylation level was statistically significant (p = 0.0105
and 0.0434, respectively) (Fig. 4g). IL-19, IL-20 and IL-24
did not affect the phosphorylation levels of ERK-1/2, JNK,
STAT1, STAT5, or STAT6 (data not shown).
Functional influences of IL-20 on migration and adhesion
receptor shedding in MDDCs
To investigate the functional consequences of IL-20 me-
diated signaling in MDDCs, an analysis linking IL-20 to
known properties of DCs or LC in skin (notably in
psoriatic skin lesions) was required. Several lines of
evidence suggested the importance of these cells in
transporting the Ag into draining lymph nodes. Add-
itionally, the report by Cumberbatch et al. [9], sug-





Fig. 3 IL-20 receptor mRNA expression in LPS and IL-20-treated
MDDCs. MDDCs were treated with LPS or IL-20, followed by isolation
and quantification of mRNA transcripts from the IL20RA (a,b), IL20RB
(c,d), or IL22R (e,f) genes by qRT-PCR. For each analysis, cells from
six donors were used with the IL-20 receptor gene transcription
normalization to the GAPDH mRNA transcripts. Results were based





Fig. 4 p38 MAPK and STAT3 phosphorylation in MDDCs pretreated
by cytokines from the IL-10 family. Phosphorylation of p38 was
measured for Thr-180 and Tyr-182 and for Tyr-705 in STAT3. Data
were based on cellular cultures derived from 3 donors and measured
in duplicates. The data are shown as the mean values of (arbitrary)
fluorescence units with error bars indicating the SD. Interleukin
pretreatment was started 10 min before harvest with the cytokines
added at concentrations (ρIL) of 0.001, 0.1, 1, or 10 ng/ml (Incubation V
in Fig. 1b) and compared with cultures without cytokine addition.
The influence was tested of IL-10 on p38 (a) and STAT3 (b)
phosphorylation, and similarly for IL-19 (c,d), IL-20 (e,f), and IL-24 (g,h)
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For in vitro analysis of MDDC migration we used a
modified Boyden chamber assay with fluorescence label-
ing of the MDDCs. The influence of IL-19, IL-20, and
IL-24 was probed by pre-incubation of the cells with the
interleukins before applying the cells into the upper
chamber where an ECM-like matrix covered a porous
membrane. To stimulate migration, human AB serum
was added as a chemoattractant in the lower chamber.
Pre-incubations with interleukins were carried over a
broad range from 0–10 ng/ml (Fig. 5). In four of five do-
nors, a peak in the number of migrated cells was ob-
served following pre-incubations with 0.1–1.0 ng/ml of
IL-20 (Fig. 5a). However, to obtain a robust statistical
analysis of the collected set of data, we used the quad-
ratic polynomial described by Eq. 2 in order to establish
a connection between the interleukin concentration and
MDDCs migration. This approach returned a statistical
significant (p < 0.0001) model with a biphasic migra-
tion response to pre-incubation with IL-20 (Fig. 5a).
The constants a, b and c in Eq. 2 were estimated
0.045 ± 0.011, -0.046 ± 0.013, and 0.439 ± 0.091, re-
spectively (indicated as the estimated value ± standard
error). The coefficient for the quadratic part of Eq. 2 (a)
was highly significant (p = 0.0004). This implies that the
quadratic part cannot be ignored in the curve fitting and
thus suggesting a biphasic response to the treatment with
IL-20. By contrast, pre-incubation with IL-19 or IL-24
did not support any significant statistical connection
between the applied interleukin concentration and mi-
gration (Fig. 5b,c). To further explore this point, we
also calculated the expected mean response to pre-
incubation with IL-20, IL-19 and IL-24 (Fig. 5a-c).
This comparison showed that that IL-20 was able to
induce a migration approximately 2-fold higher than
the base line or in the MDDCs cultures treated with
IL-19 and IL-24 (Fig. 5d).
We also tested whether IL-20 acted as a chemoattract-
ant for MDDCs (Fig. 5e). In this case, IL-20 was added
to the lower part of the Boyden chamber. The migration
of MDDCs from four of the five donors showed no abil-
ity of IL-20 to attract the MDDCs. By contrast, addition






Fig. 5 Influence of IL-10 family interleukins on MDDCs migration.
a-d The migration of MDDCs towards an AB human serum gradient
through an ECM-like coagulate on a membrane with 8-μm pores in
a modified Boyden chamber. The MDDCs were incubated with or
without addition of IL-19, IL-20, or IL-24 at concentrations (ρIL) of
0.0001, 0.001, 0.01, 0.1, 1.0, or 10 ng/ml for 30 min. a Migration of
IL-20-pretreated MDDCs derived. b Migration of IL-19 pretreated-
MDDCs. c Migration of IL-24 pretreated-MDDCs. d Summary of
the dose-response curves. e Analysis of the role of IL-20 as a
chemoattractant for MDDCs where IL-20 applied in the lower
chamber (instead of AB serum)
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migration (Fig. 5e). This finding was supported by the
statistical significance of the curve fitting (p = 0.0379) ac-
cording to Eq. 2. The maximal effect was observed fol-
lowing treatment with 0.1 and 1 ng/ml of IL-20. This
influence of IL-20 was clearly titratable and vanished at
concentrations lower than 0.01-0.01 ng/ml. While Eq. 2
was able to account for the data, it should be noted that
an even simpler approach using a simple linear relation-
ship between the IL-20 concentrations produced a stron-
ger significance (p = 0.0226).
Cell migration, in particular that mediated by integ-
rins, is closely linked with mechanisms supporting adhe-
sion. Recent studies shown that β2 (CD18) integrins are
shed from the leukocyte cell surface in inflammatory dis-
eases and under certain experimental conditions in vitro
[13, 15]. We employed assays described earlier [13] to
analyze the connection between IL-20 and CD18 integ-
rin shedding.
A simple way of monitoring alterations in cellular ad-
hesion involves microscopy of surface-bound cells [24].
During the culture of MDDCs we observed that IL-20-
exposed cultures showed subtle, yet persistent, changes
in overall morphology and cellular distribution com-
pared with untreated controls. In Fig. 6 such changes are
shown for cells derived from Donor #61 (Fig. 6a,c) and
#62 (8B,D). The observation of that IL-20 treated cells
(Fig. 6c,d) were more likely to form clusters than non-
treated cells (Fig. 6a,b) suggests that intercellular
adhesion was changed. However, as demonstrated by
treatment with TNFα (Fig. 6e,f ), the donor variations
were large and the types of morphological changes were
difficult to characterize by uniform parameters.
Soluble CD18 levels in the supernatants were mea-
sured to quantify the processes relevant to cellular adhe-
sion in MDDCs derived from seven donors, following
seven days of culture with addition of cytokines on
Day 6 (Fig. 6g,h) [13]. IL-20 was applied in concen-
trations ranging 0.0001 to 5000 ng/ml. In Fig. 6g, the
sCD18 concentration was plotted as a function of the
IL-20 concentration. Testing with ANOVA whether
the mean value for sCD18 in each group of IL-20
treatments were equal was rejected with p = 0.0256
(Fig. 6g). In the interval between 0.0001 and 1000 ng/ml
(marked by grey arrows), the profile of IL-20-influenced
shedding showed a tendency towards a biphasic response,
where the lowest shedding occurred for treatment
with 0.01–10 ng/ml relative to either lower or higher
dosages (Fig. 6g). Previously, we observed that CD18
shedding requires viable cells [13], and hence we sus-
pected this biphasic pattern could be due to cell
death. However, analyses with flow cytometry did not
support this explanation (data not shown). TNFα was
previously reported to enhance CD18 shedding in cul-
tures of human mononuclear leukocytes and granulocytes
[13]. However, application of this cytokine to the cul-
tures of MDDCs moderately reduced the shedding
(Fig. 6h). In this case, visual inspection of the cellular
cultures indicated some loss of viable cells in the
wells (Fig. 6e-f ).
Importantly, Gjelstrup et al. [13] reported the finding
of large oligomeric species of CD18 in human plasma
and in recombinant soluble CD11a/CD18. Crystallo-
graphic data [25] suggested that the oligomers contained
from two chains (1 × CD11a/CD18) up to at least a total
of eight chains (4 × CD11a/CD18). However, it has never





Fig. 6 Adhesive properties of cytokine-treated MDDCs. Cells were
incubated with IL-20 or TNFα prior to microscope imaging (a-f) or
analysis of β2 (CD18) integrin adhesion molecules shedding (g,h).
MDDCs were imaged either as untreated (a,b), following treatment
with 0.01 ng/ml IL-20 (c,d), or with 100 ng/ml TNFα (e,f). g,h CD18
shedding from MDDCs treated with cytokines. Based on cells from
seven donors (#60-#66), culture supernatants from cytokine-treated
MDDCs were applied in analyses of the concentration of sCD18.
Comparison of sCD18 concentration (in mU/ml) obtained from
either untreated cultures, cultures stimulated with 0.01-5000 ng/ml
of IL-20 (g), or 1-100 ng/ml of TNFα (h)
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cellular cultures and what conditions may affect the olig-
omeric size.
Supernatant from two independent cultures of MDDC
were analyzed by GPC (Fig. 7). For comparison, the
CD18 oligomeric profile in human citrate plasma was
also included (Fig. 7a). In both IL-20-treated (Fig. 7c,d)
and untreated cultures (Fig. 7b), the CD18 oligomers
were mainly distributed in two peaks eluting at the col-
umn void volume and in volumes corresponding to a
hydrodynamic radius of ~8 nm. As indicated with
hatched lines this corresponds to the size of complexes
also found in plasma and in recombinant soluble
CD11a/CD18. By contrast, the oligomers eluting in the
void volume (Fig. 7b-d) had no corresponding oligomers
in plasma (Fig. 7a). To study the influence of IL-20 on
oligomer size, the raw data (Fig. 7b-c) were analyzed by
plotting the cumulative distribution of CD18 signals in
the fraction eluting with Ve from 34 to100 ml (Fig. 7e,f ).
In the supernatants from Donor #67, it was clear that
treatment with 1 ng/ml of IL-20 reduced the abundance
of oligomers with a RH larger than ~ 7.5 nm compared
with either no treatment or treatment with 5,000 ng/ml
IL-20. By contrast, treatment with 5000 ng/ml appeared
to induce a small increase in the abundance of these lar-
ger oligomers compared with either of the two other
culture conditions. Qualitatively these difference were
also found for Donor #68 (Fig. 7f ), even with shared de-
tailed features in the distribution profile (indicated with
black arrows in Fig. 7e,f ), albeit the quantitative differ-
ence was smaller for this donor.
Fig. 7 Distribution of sCD11/CD18 oligomers in MDDCs culture
supernatants. a GPC followed by TRIFMA detection of sCD11/CD18
in a “sandwich-type” assay with the monoclonal Ab KIM185 to CD18
as a capture Ab and KIM127. The plot shows the TRIFMA signal (STRF,
read on the left ordinate) and the optical density (OD) at λ = 280 nm
(read on the right ordinate) in the fractions plotted as a function of
the elution volume, Ve. The elution volumes of oligomeric recombinant
soluble CD11a/CD18 (established in a previous study [13] using
the same chromatography equipment) are indicated hatched lines
together with the elution volumes of the hydrodynamic radius
calibration markers thyroglobulin, ferritin, IgG, and albumin. b-d
Distribution of sCD11/CD18 oligomers in cell culture supernatant
from MDDCs. The analysis was carried out with culture supernatants
derived from two Donors (#67 and #68), either left untreated or treated
with 1 or 5000 ng/ml IL-20 (Incubation VII in Fig. 1b) The sCD11/CD18
signal in the fractions was measured with the KIM185-KIM127 assay
and plotted as a function of Ve. (e,f) Cumulative distribution of the
CD18 signal in the GPC fractions. The cumulative distribution profile




as a function of
Ve, where STRF(Ve) is the CD18 signal for the fraction with elution
volume Ve and ∑STRF the sum of signals for all fractions eluting
from 30 ml to 100 ml, both end points included. Black arrows indicate
a feature in the distribution profile shared between the donors
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Conclusion
We established in vitro culture conditions that enabled a
phenotypic expression of cell surface markers mimicking
the immature DCs in humans, further confirmed by the
vigorous response of these cells to LPS-induced matur-
ation. Pretreatment of the MDDCs with IL-20 resulted
in an increased CD86 expression. CD86 contributes to
the formation of the immunological synapse between
DCs and T-cells [21, 26, 27], which is critical in the de-
velopment of psoriasis. Only high IL-20 concentrations
(500-5000 ng/ml) resulted in a significant increase in the
CD86 positive cells. As a comparison, the mean con-
centration of IL-20 in serum from patients suffering
rheumatoid arthritis was reported to be 0.282 ng/ml
[3]. However, the local environment of the psoriatic
epidermis, which includes the IL-20 producing kerati-
nocytes and MDDCs in close proximity, is likely to
present IL-20 concentrations higher than the systemic
concentration [28].
Previous studies found transcription of mRNA in
MDDCs encoding the IL-20RB chain, while transcripts
encoding IL-20RA or IL-22R were not reported [6] or
only found in trace amounts [29]. By testing the imma-
ture MDDCs, transcripts encoding IL-20RA and IL-
20RB were detected, albeit only weakly, suggesting the
formation of functional receptor complexes in the mem-
brane of MDDCs.
No previous reports addressed the IL-20-induced sig-
nal transduction in leukocytes. In MDDCs, IL-20 and
IL-24 induced p38 phosphorylation in MDDCs, while
IL-10 and IL-19 did not. IL-24 was the most potent
stimulator of the p38 MAPK pathway, while IL-20
showed a weaker mean phosphorylation. For both IL-20
and IL-24 the most potent response was observed for
treatment with 0.1 ng/ml interleukin.
Cumberbatch et al. reported that Langerhans cells are
trapped in non-lesional psoriatic skin [9]. IL-20 is known
to affect migration of neutrophils, chemotaxis of syn-
ovial fibroblasts chemotaxis in rheumatoid arthritis, and
vascular tube-formation by endothelial cells [30, 31].
Our findings now suggest that IL-20 potentiates MDDCs
migration towards a chemoattractant. IL-20 itself did
not act as a chemoattractant but decreased migration in
higher IL-20 concentrations. Interestingly, in our study a
similar influence by other IL-10 interleukin family mem-
bers, i.e., IL-19 and IL-24, was not found. A simple
explanation, in agreement with the observations for the
IL-20-mediated signaling in MDDCs, was offered re-
cently by a structural characterization of the ternary
complex between IL-20 and the IL20-A/IL-20B receptor.
From these data as well as direct measurements of the
binding of IL-20 and IL-19, it appeared that the IL-19
binds to the IL-20A/IL-20B receptor 10-fold weaker
than IL-20 [32].
Based on the hypothesis that CD18 shedding is critical
for the migration of myeloid cells [33, 34], we analyzed
the influence of IL-20 on CD18 shedding in cultures of
MDDCs. As in the case of the migrational influence of
IL-20, no simple relation between the applied IL-20 con-
centration and CD18 shedding was found. However,
there was an indication that IL-20 in the concentration
interval 0.01-10 ng/ml induced lower shedding than
either lower or higher concentrations. A more detailed
investigation was carried out by analyzing the CD18
oligomer size distribution in cultures treated with IL-20
compared to untreated controls. The most striking effect
was again observed for treatment with 1 ng/ml IL-20,
which apparently was able to reduce the relative abun-
dance of larger oligomers, albeit with marked differences
in the quantitative response among the two independent
cultures tested. Nevertheless, our data suggest that not
only the level of shedding but also the CD18 oligomer
size is variable influenced by cytokine stimulation of
MDDC. This proposal seems entirely consistent with
the multiple capacities of the complex proteolytic
mechanisms responsible for regulating the shedding
[16, 33, 35]. Interestingly, the observation that such
changes occurs by treatment with 1 ng/ml IL-20,
which was also found to affect migration suggest a
potential link between the structural formation of
CD18 oligomers and migration.
In conclusion, our findings suggest that IL-20 has an
influence on processes central to the function of DCs.
However, the responses found in our report and in the
work by others were either weak or subject to consider-
able donor variation. This situation questions if IL-20 is
a significant part of the normophysiological functions of
DCs. Our findings may propose an aberrant influence of
IL-20 in the case of the high concentrations as often
found in psoriasis.
Additional file
Additional file 1: Figure S1. LPS-induced maturation of MDDCs
monitored by the expression of cell surface markers. For each maturation
marker the expression was investigated in culture receiving LPS treatment
(10 ng per ml of culture medium, indicated as Incubation II in Fig. 1b) or in
control cultures receiving treatment with vehicle only (indicated as
Incubation I in Fig. 1b). The percentage of marker-positive cells were
established by flow cytometry staining for HLA-DR (A), CD1a (B), CD1c (C),
CD40 (D), CD80 (E), CD83 (F), CD86 (G), and CD14 (H). Results were based
on MDDCs from Donors #1-25. The p value (indicated in italics) was
calculated using a two-tailed Student’s t-test. (PDF 282 kb)
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